Elanco Animal Health Incorporated

Fundamentals6.0
Price Action3.0
News Sentiment7.0
AI Rating
6.0

Key Drivers

  • Margin Recovery
  • Debt 부담
  • Cash Volatility

AI
AI Summary

6.0

ELAN's Q1 revenue acceleration, raised guidance, and improving margins suggest the turnaround is now becoming a real operating inflection, but the stock still hinges on whether management can translate that momentum into consistent free cash flow and debt reduction before leverage and thin reported profitability reassert pressure.

GrowthOpportunity
ExecutionRisk
Leverage‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Margin Recovery
  • Debt 부담
  • Cash Volatility

ELAN is improving operationally with better margins and liquidity, but leverage, intangibles, uneven cash flow, and a rich valuation keep the risk-reward mixed.

ImprovingMargins
LeverageRisk

Price Behavior

3.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Lower highs
  • Support breakdown
  • Oversold bounce

ELAN has shifted into a bearish short-term downtrend over the last month, breaking $21.4–$21.7 support and remaining vulnerable unless $19.86 holds and price quickly reclaims $21.4–$22.0.

bearish
downtrend
Support Level: $19.86
Resistance Level: $21.4–$22.0

Sharp selloff from $26.18 on 2026-05-06 to $19.86 with lower highs and lower lows

Sentiment & News

7.0

Key News Insights:

  • Q1 Beat
  • Guidance Raise
  • Screwworm Approvals

Elanco's strong Q1 beat, raised guidance, and new product approvals point to improving growth momentum and continued balance-sheet progress.

EarningsBeat
ProductMomentum

The news is likely supportive for ELAN as stronger execution and product momentum improve near-term outlook and investor confidence